SLC2A1 and type 2 diabetes mellitus: The potential beneficial effect of using SIRT-6 inhibitors in T2D came also from an independent study, in which Compound 6d (a newly identified SIRT-6 inhibitor) was used in a mouse model of T2D and significantly increased the level of glucose transporter GLUT-1, thereby reducing blood glucose [181].